XSHE
002581
Market cap507mUSD
Oct 09, Last price
5.24CNY
1D
1.75%
1Q
58.79%
Jan 2017
-78.41%
IPO
-35.73%
Name
Shandong Sinobioway Biomedicine Co Ltd
Chart & performance
P/E
—
P/S
12.58
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.04%
Rev. gr., 5y
-7.36%
Revenues
275m
-23.75%
Net income
-116m
L-15.32%
CFO
-254m
L+3,775.50%
Dividend
Jun 21, 20160.05 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, manufacture, and sale of chemical raw materials, chemical and pharmaceutical products. Its products include pharmaceutical intermediates and pesticide intermediates. The company was founded on January 18, 2000 and is headquartered in Beijing, China.
Key people
Juanxiong Xu
Vice Chairman of the Board, Deputy General Manager · since 2025
Ting Zhou
Chief Financial Officer · since 2024
Jialin Yue
Chairman of the Board, General Manager · since 2022
Xing Chen
Deputy General Manager, Director · since 2025
Lijun Wang
Deputy General Manager · since 2020
Yi'nuo Zhang
Deputy General Manager, Director · since 2018
Xiaoru Shi
Secretary of the Board · since 2024
Guiyuan Huang
Director · since 2022
Wenjun Liu
Director · since 2024
Ying Yue
Director · since 2023
Yanhong Cai
Independent Director · since 2024
Yang Liu
Independent Director · since 2022
Yong Rao
Independent Director · since 2019
Yang Xia
Independent Director · since 2022
Jun Yang
Independent Director · since 2025
Rongfu Zhang
Independent Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||